EUCTR2011-005540-99-AT进行中（未招募）1 期
Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced or not resectable Carcinoma of the Head and Neck - AGMT_HNO2
AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH0 个研究点目标入组 100 人开始时间: 2013年1月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed local advanced squamous cell carcinoma of the Larynx, Hypopharynx, Oropharynx or Cavum oris stage III and IV
- •One measureable lesion (CT oder MR)
- •Age 18 – 75 (including)
- •Performance Score ECOG 0 – 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Distant metastases
- •ECOG Score >1
- •Prior radiation (Head and neck area)
- •Creatinin Clearance below 60 ml/µl
- •Acute infections
- •Neuropathy grade 3 or 4
- •Myocardial Infarction within the last 12 months
- •Acute coronary syndrom or othe clinically significant cardiovascular diseases
研究者
相似试验
进行中（未招募）
1 期
Comparison of two treatment arms of patients with non-small cell lung cancer. Patients of one arm receive the authorized infusion Durvalumab after chemotherapy, chemotherapy with radiotherapy and optional resection. Patients in the second treatment arm receive Durvalumab from the beginning, in parallel with standard therapy.non-small cell lung cancer stages IIIA (N2) and selected resectable stages IIIBMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000058-77-DEniversity Hospital Essen90
进行中（未招募）
不适用
A phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with malignantpleural mesothelioma.MedDRA version: 7.1Level: SOCClassification code 10029104malignant pleural mesotheliomaEUCTR2004-004273-28-GBEuropean Organisation for Research and Treatment of Cancer52
进行中（未招募）
1 期
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineEUCTR2009-016142-44-DEniversity Hospital Ulm336
进行中（未招募）
1 期
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineEUCTR2009-016142-44-ATniversity Hospital Ulm336
进行中（未招募）
不适用
Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinomnbehandeltes, histologisch gesichertes, nicht-metastasiertes Ösophaguskarzinom (Plattenepithelkarzinom)MedDRA version: 9.1Level: LLTClassification code 10056104Term: Squamous cell carcinoma of oesophagusEUCTR2008-001016-21-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH